

**Tumor Board Tuesday – Dr. Hossein Borghaei, 08/30/2022:  
Stage III Unresectable NSCLC**

**Posttest Rationale**

**1. What adjuvant treatment would you select for a patient with unresectable stage III NSCLC initially treated with definitive chemoradiation?**

- a. Chemotherapy
- b. Durvalumab**
- c. Observation
- d. Osimertinib

**Rationale:** Durvalumab is FDA indicated for the treatment of adult patients with unresectable, stage III NSCLC whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy. Neither chemotherapy, observation, nor osimertinib are appropriate adjuvant treatment options in this scenario.

**References:** IMFINZI® (durvalumab) [prescribing information]. AstraZeneca. Approved 2017. Revised July 2021. [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2021/761069s028lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761069s028lbl.pdf)

National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): Non-Small Cell Lung Cancer (v3.2022). Updated March 16, 2022. Accessed April 13, 2022. [https://www.nccn.org/professionals/physician\\_gls/pdf/nscl.pdf](https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf)

**2. What treatment regimen would you select for a patient with unresectable stage 3 NSCLC and 36% PD-L1 expression who received adjuvant durvalumab treatment?**

- e. Atezolizumab + chemo
- f. Nivolumab + ipilimumab
- g. Nivolumab + ipilimumab + chemo
- h. Pembrolizumab + chemo**

**Rationale:** Pembrolizumab + pemetrexed + (carboplatin or cisplatin) is the NCCN guideline-preferred treatment regimen for this patient; the other options are listed as “other recommended” or “useful in certain circumstances”.

**Reference:** National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): Non-Small Cell Lung Cancer (v3.2022). Updated March 16, 2022. Accessed April 13, 2022. [https://www.nccn.org/professionals/physician\\_gls/pdf/nscl.pdf](https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf)